American Heart Association Institute For Precision Cardiovascular Medicine Now Accepting Applications For New Research Grants
Three AHA-Bayer Innovation and Discovery awards seek high impact advances in cerebral small vessel disease, chronic kidney disease and heart failure
DALLAS – February 16, 2017 – The American Heart Association (AHA) Institute for Precision Cardiovascular Medicine, the only organization dedicated exclusively to advancing precision medicine in cardiovascular care, announced it is now accepting applications for new research grants in three critical areas: cerebral small vessel disease, chronic kidney disease and heart failure. The AHA-Bayer Innovation and Discovery Grants, funded by Bayer, will provide $150,000 to each investigator. Insight into these specific areas using precision medicine may advance scientific understanding and address unmet medical needs in cardiovascular and kidney diseases.
Researchers from around the world are encouraged to apply. Applications are now being accepted at http://research.americanheart.org and are due on April 13, 2017. Three awardees will be notified in June 2017 and the 18-month awards begin on July 1, 2017.
“Research in each of these areas is critical to provide individuals with better prevention and treatment options,” said AHA Institute for Precision Cardiovascular Medicine Chief, Jennifer Hall, Ph.D., FAHA. “Through this collaboration with Bayer, the American Heart Association is able to support vital research to develop a deeper understanding of these diseases.”
About Cerebral Small Vessel Disease
Cerebral small vessel disease accounts for approximately 25–30 percent of strokes and are a leading cause of age- and hypertension-related cognitive decline and disability. The specific treatments for cerebral small vessel disease are lacking, and therapeutic options for secondary prevention are limited compared to other common causes of stroke.
About Chronic Kidney Disease
Chronic kidney disease and end-stage renal disease are major health burdens worldwide, affecting an estimated 200 million people. Cardiovascular disease is the leading cause of morbidity and mortality in patients with chronic kidney disease. Notably, chronic kidney disease is an interesting clinical model of accelerated cardiovascular disease and ageing, which offers new perspectives for pharmaceutical drug development.
About Heart Failure
Nearly half of all patients with heart failure have a normal ejection fraction. The prevalence of this syndrome, termed heart failure with preserved ejection fraction, continues to increase in the developed world with the increasing prevalence of common risk factors. These factors include older age, gender, hypertension, metabolic syndrome, renal dysfunction and obesity. Although Heart Failure with preserved ejection fraction affects 50 percent of all heart failure patients, there is a lack of consensus on the basic pathophysiology and definition, classification, therapeutic targets, and goals for therapy for this syndrome.
Data resulting from the projects may be included in the AHA Precision Medicine Platform powered by Amazon Web Services. The AHA Precision Medicine Platform is a cloud-based data marketplace where scientists from around the world can store, share and analyze research data. Making that data available in the cloud accelerates research with the aim to find cures for cardiovascular diseases, the top cause of death worldwide. For more information on the Precision Medicine Platform and the Institute for Precision Cardiovascular Medicine, visit http://precision.heart.org and http://institute.heart.org.
# # #
About Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.us. Our online press service is just a click away: http://www.press.bayer.com. Follow us on Facebook and Twitter.
About the American Heart Association
The American Heart Association is devoted to saving people from heart disease and stroke – two of the leading causes of death in the world. We team with millions of volunteers to fund innovative research, fight for stronger public health policies, and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is one of the world’s oldest and largest voluntary organizations dedicated to fighting heart disease and stroke. To learn more or to get involved, visit www.heart.org or follow us on Facebook and Twitter.
About the AHA Institute for Precision Cardiovascular Medicine
The American Heart Association Institute for Precision Cardiovascular Medicine is the only organization dedicated exclusively to advancing precision medicine in cardiovascular care. The Institute aims to preserve and prolong health by architecting more precise scientific discoveries – those that take into account a person’s genetics, environment and lifestyle – for better prevention and treatment of cardiovascular diseases and stroke. To learn more, apply for research grants or to get involved, visit http://institute.heart.org.
The American Heart Association/American Stroke Association receives funding mostly from individuals. Foundations and corporations donate as well, and fund specific programs and events. Strict policies are enforced to prevent these relationships from influencing the association’s science content. Financial information for the American Heart Association, including a list of contributions from pharmaceutical companies and device manufacturers, is available at www.heart.org/corporatefunding.
Suzanne Grant, 214-706-2948
American Heart Association, Media Relations